Preferences help
enabled [disable] Abstract
Number of results
2008 | 55 | 3 | 559-570
Article title

p53-dependent suppression of the human calcyclin gene (S100A6): the role of Sp1 and of NFκB

Title variants
Languages of publication
Calcyclin (S100A6) is believed to participate in cell cycle control. It was, however, unclear if its expression depends on p53, a key regulator of apoptosis and cell cycle. We therefore performed transcription regulation assays in HeLa cells and found that wild type p53 suppressed the S100A6 promoter up to 12-fold in a dose-dependent manner. In contrast, the well-characterized V143A, R175H, R249S, and L344A p53 mutants cloned from human cancers suppressed this promoter with a 6 to 9-fold lower efficiency. All the sites mediating the p53-dependent suppression were contained in the -167 to +134 fragment of the S100A6 promoter. Separate overexpression of either Sp1 or of NFκB only partially counteracted the p53 inhibitory effect on the S100A6 promoter, while simultaneous overexpression of both these transactivators resulted in a complete abolishment of the p53 inhibitory effect on this promoter. Sp1 and NFκB binding to the probes resembling their putative binding sites present in the S100A6 promoter was decreased in the presence of wild type p53. We propose that the suppression of S100A6 is yet another mechanism by which p53 inhibits proliferation. Insufficient suppression of this gene by p53 mutants could well be responsible for calcyclin overexpression and cell cycle deregulation observed in cancer tissues.
Physical description
  • Department of Biochemistry, Medical Center of Postgraduate Education, Warszawa, Poland
  • Department of Biochemistry and Molecular Biology, Medical Research Center, Polish Academy of Sciences, Warszawa, Poland
  • Department of Biochemistry, Medical Center of Postgraduate Education, Warszawa, Poland
  • Alvarez-Chaver P, Rodriguez-Pineiro AM, Rodriguez-Berrocal FJ, Martinez-Zorzano VS, Paez de la Cadena M (2007) Identification of hydrophobic proteins as biomarker candidates for colorectal cancer. Int J Biochem Cell Biol 39: 529-540.
  • Bargonetti J, Chicas A, White D, Prives C (1997) p53 represses Sp1 DNA binding and HIV-LTR directed transcription. Cell Mol Biol 43: 935-949.
  • Berta GN, Ghezzo F, D'Avolio A, Zulian P, Carbone V, Racca S, Vercellino V, Di Carlo F (1997) Enhancement of calcyclin gene RNA expression in squamous cell carcinoma of the oral mucosa, but not in benign lesions. J Oral Pathol Med 26: 206-210.
  • Blagosklonny MV (2000) p53 from complexity to simplicity: mutant p53 stabilization, gain-of-function, and dominant-negative effect. FASEB J 14: 1901-1907.
  • Brown LM, Helmke SM, Hunsucker SW, Netea-Maier RT, Chiang SA, Heinz DE, Shroyer KR, Duncan MW, Haugen BR (2006) Quantitative and qualitative differences in protein expression between papillary thyroid carcinoma and normal thyroid tissue. Mol Carcinog 45: 613-626.
  • Cheng CW, Rifai A, Ka SM, Shui HA, Lin YF, Lee WH, Chen A (2005) Calcium-binding proteins annexin A2 and S100A6 are sensors of tubular injury and recovery in acute renal failure. Kidney Int 68: 2694-2703.
  • Cross SS, Hamdy FC, Deloulme JC, Rehman I (2005) Expression of S100 proteins in normal human tissues and common cancers using tissue microarrays: S100A6, S100A8, S100A9 and S100A11 are all overexpressed in common cancers. Histopathology 46: 256-269.
  • Donato R (2003) Intracellular and extracellular roles of S100 proteins. Microsc Res Tech 60: 540-551.
  • Farmer G, Colgan J, Nakatani Y, Manley JL, Prives C (1996) Functional interaction between p53, the TATA-binding protein (TBP), and TBP-associated factors in vivo. Mol Cell Biol 16: 4295-4304.
  • Farnaes L, Ditzel HJ (2003) Dissecting the cellular functions of annexin XI using recombinant human annexin XI-specific autoantibodies cloned by phage display. J Biol Chem 278: 33120-33126.
  • Ferrari S, Tagliafico E, Manfredini R, Grande A, Rossi E, Zucchini P, Torelli G, Torelli U (1992) Abundance of the primary transcript and its processed product of growth-related genes in normal and leukemic cells during proliferation and differentiation. Cancer Res 52: 11-16.
  • Filipek A, Kuznicki J (1993) Calcyclin - from basic research to clinical implications. Acta Biochim Polon 40: 321-327.
  • Filipek A, Puzianowska M, Cieslak B, Kuznicki J (1993) Calcyclin-Ca(2+)-binding protein homologous to glial S-100 beta is present in neurones. Neuroreport 4: 383-386.
  • Ghezzo F, Lauret E, Ferrari S, Baserga R (1988) Growth factor regulation of the promoter for calcyclin, a growth-regulated gene. J Biol Chem 263: 4758-4763.
  • Harris LC, Remack JS, Houghton PJ, Brent TP (1996) Wild-type p53 suppresses transcription of the human O6-methylguanine-DNA methyltransferase gene. Cancer Res 56: 2029-2032.
  • Heizmann CW, Fritz G, Schafer BW (2002) S100 proteins: structure, functions and pathology. Front Biosci 7: d1356-d1368.
  • Hernandez-Boussard T, Rodriguez-Tome P, Montesano R, Hainaut P (1999) IARC p53 mutation database: a relational database to compile and analyze p53 mutations in human tumors and cell lines. International Agency for Research on Cancer. Hum Mutat 14: 1-8.
  • Hirschhorn RR, Aller P, Yuan ZA, Gibson CW, Baserga R (1984) Cell-cycle-specific cDNAs from mammalian cells temperature sensitive for growth. Proc Natl Acad Sci USA 81: 6004-6008.
  • Hoppe-Seyler F, Butz K (1993) Repression of endogenous p53 transactivation function in HeLa cervical carcinoma cells by human papillomavirus type 16 E6, human mdm-2, and mutant p53. J Virol 67: 3111-3117.
  • Houser S, Koshlatyi S, Lu T, Gopen T, Bargonetti J (2001) Camptothecin and Zeocin can increase p53 levels during all cell cycle stages. Biochem Biophys Res Commun 289: 998-1009.
  • Iwao T, Hanada K, Tsuchida A, Hirata M, Eguchi N, Kajiyama G (1998) The establishment of a preoperative diagnosis of pancreatic carcinoma using cell specimens from pancreatic duct brushing with special attention to p53 mutations. Cancer 82: 1487-1494.
  • Jang JS, Cho HY, Lee YJ, Ha WS, Kim HW (2004) The differential proteome profile of stomach cancer: identification of the biomarker candidates. Oncol Res 14: 491-499.
  • Kim J, Kim J, Yoon S, Joo J, Lee Y, Lee K, Chung J, Choe I (2002) S100A6 protein as a marker for differential diagnosis of cholangiocarcinoma from hepatocellular carcinoma. Hepatol Res 23: 274-286.
  • Komatsu K, Andoh A, Ishiguro S, Suzuki N, Hunai H, Kobune-Fujiwara Y, Kameyama M, Miyoshi J, Akedo H, Nakamura H (2000) Increased expression of S100A6 (Calcyclin), a calcium-binding protein of the S100 family, in human colorectal adenocarcinomas. Clin Cancer Res 6: 172-177.
  • Kuznicki J, Kordowska J, Puzianowska M, Wozniewicz BM (1992) Calcyclin as a marker of human epithelial cells and fibroblasts. Exp Cell Res 200: 425-430.
  • Lesniak W, Jezierska A, Kuznicki J (2000) Upstream stimulatory factor is involved in the regulation of the human calcyclin (S100A6) gene. Biochim Biophys Acta 1517: 73-81.
  • Li B, Lee MY (2001) Transcriptional regulation of the human DNA polymerase δ catalytic subunit gene POLD1 by p53 tumor suppressor and Sp1. J Biol Chem 276: 29729-29739.
  • Martin AC, Facchiano AM, Cuff AL, Hernandez-Boussard T, Olivier M, Hainaut P, Thornton JM (2002) Integrating mutation data and structural analysis of the TP53 tumor-suppressor protein. Hum Mutat 19: 149-164.
  • Ohlsson C, Kley N, Werner H, LeRoith D (1998) p53 regulates insulin-like growth factor-I (IGF-I) receptor expression and IGF-I-induced tyrosine phosphorylation in an osteosarcoma cell line: interaction between p53 and Sp1. Endocrinology 139: 1101-1107.
  • Ohuchida K, Mizumoto K, Yu J, Yamaguchi H, Konomi H, Nagai E, Yamaguchi K, Tsuneyoshi M, Tanaka M (2007) S100A6 is increased in a stepwise manner during pancreatic carcinogenesis: clinical value of expression analysis in 98 pancreatic juice samples. Cancer Epidemiol Biomarkers Prev 16: 649-654.
  • Okazaki K, Niki I, Iino S, Kobayashi S, Hidaka H (1994) A role of calcyclin, a Ca2+-binding protein, on the Ca2+-dependent insulin release from the pancreatic β cell. J Biol Chem 269: 6149-6152.
  • Olivier M, Hussain SP, Caron de Fromentel C, Hainaut P, Harris CC (2004) TP53 mutation spectra and load: a tool for generating hypotheses on the etiology of cancer. IARC Sci Publ 157: 247-270.
  • Petitjean A, Achatz MI, Borresen-Dale AL, Hainaut P, Olivier M (2007) TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes. Oncogene 26: 2157-2165.
  • Ragimov N, Krauskopf A, Navot N, Rotter V, Oren M, Aloni Y (1993) Wild-type but not mutant p53 can repress transcription initiation in vitro by interfering with the binding of basal transcription factors to the TATA motif. Oncogene 8: 1183-1193.
  • Redston MS, Caldas C, Seymour AB, Hruban RH, da Costa L, Yeo CJ, Kern SE (1994) p53 mutations in pancreatic carcinoma and evidence of common involvement of homocopolymer tracts in DNA microdeletions. Cancer Res 54: 3025-3033.
  • Santamaria-Kisiel L, Rintala-Dempsey AC, Shaw GS (2006) Calcium-dependent and -independent interactions of the S100 protein family. Biochem J 396: 201-214.
  • Sengupta S, Shimamoto A, Koshiji M, Pedeux R, Rusin M, Spillare EA, Shen JC, Huang LE, Lindor NM, Furuichi Y, Harris CC (2005) Tumor suppressor p53 represses transcription of RECQ4 helicase. Oncogene 24: 1738-1748.
  • Seto E, Usheva A, Zambetti GP, Momand J, Horikoshi N, Weinmann R, Levine AJ, Shenk T (1992) Wild-type p53 binds to the TATA-binding protein and represses transcription. Proc Natl Acad Sci USA 89: 12028-12032.
  • St Clair S, Giono L, Varmeh-Ziaie S, Resnick-Silverman L, Liu WJ, Padi A, Dastidar J, DaCosta A, Mattia M, Manfredi JJ (2004) DNA damage-induced downregulation of Cdc25C is mediated by p53 via two independent mechanisms: one involves direct binding to the cdc25C promoter. Mol Cell 16: 725-736.
  • Stradal TB, Gimona M (1999) Ca2+-dependent association of S100A6 (Calcyclin) with the plasma membrane and the nuclear envelope. J Biol Chem 274: 31593-31596.
  • Strano S, Dell'Orso S, Di Agostino S, Fontemaggi G, Sacchi A, Blandino G (2007) Mutant p53: an oncogenic transcription factor. Oncogene 26: 2212-2219.
  • Subbaramaiah K, Altorki N, Chung WJ, Mestre JR, Sampat A, Dannenberg AJ (1999) Inhibition of cyclooxygenase-2 gene expression by p53. J Biol Chem 274: 10911-10915.
  • Szymańska K, Hainaut P (2003) TP53 and mutations in human cancer. Acta Biochim Polon 50: 231-238.
  • Thordarson G, Southard JN, Talamantes F (1991) Purification and characterization of mouse decidual calcyclin: a novel stimulator of mouse placental lactogen-II secretion. Endocrinology 129: 1257-1265.
  • Tomas A, Moss SE (2003) Calcium- and cell cycle-dependent association of annexin 11 with the nuclear envelope. J Biol Chem 278: 20210-20216.
  • Tonini GP, Fabretti G, Kuznicki J, Massimo L, Scaruffi P, Brisigotti M, Mazzocco K (1995) Gene expression and protein localisation of calcyclin, a calcium-binding protein of the S-100 family in fresh neuroblastomas. Eur J Cancer 31A: 499-504.
  • Truant R, Xiao H, Ingles CJ, Greenblatt J (1993) Direct interaction between the transcriptional activation domain of human p53 and the TATA box-binding protein. J Biol Chem 268: 2284-2287.
  • Unger T, Mietz JA, Scheffner M, Yee CL, Howley PM (1993) Functional domains of wild-type and mutant p53 proteins involved in transcriptional regulation, transdominant inhibition, and transformation suppression. Mol Cell Biol 13: 5186-5194.
  • Wang Q, Beck WT (1998) Transcriptional suppression of multidrug resistance-associated protein (MRP) gene expression by wild-type p53. Cancer Res 58: 5762-5769.
  • Webster NJ, Resnik JL, Reichart DB, Strauss B, Haas M, Seely BL (1996) Repression of the insulin receptor promoter by the tumor suppressor gene product p53: a possible mechanism for receptor overexpression in breast cancer. Cancer Res 56: 2781-2788.
  • Weterman MA, Stoopen GM, van Muijen GN, Kuznicki J, Ruiter DJ, Bloemers HP (1992) Expression of calcyclin in human melanoma cell lines correlates with metastatic behavior in nude mice. Cancer Res 52: 1291-1296.
  • Weterman MA, van Muijen GN, Bloemers HP, Ruiter DJ (1993) Expression of calcyclin in human melanocytic lesions. Cancer Res 53: 6061-6066.
  • Wojda U, Kuznicki J (1993) Biochemical properties of calcyclin - a potential marker of some diseases. Acta Biochim Polon 40: 171-175.
  • Vimalachandran D, Greenhalf W, Thompson C, Luttges J, Prime W, Campbell F, Dodson A, Watson R, Crnogorac-Jurcevic T, Lemoine N, Neoptolemos J, Costello E (2005) High nuclear S100A6 (Calcyclin) is significantly associated with poor survival in pancreatic cancer patients. Cancer Res 65: 3218-3225.
  • Xiao H, Pearson A, Coulombe B, Truant R, Zhang S, Regier JL, Triezenberg SJ, Reinberg D, Flores O, Ingles CJ, Greenblatt J (1994) Binding of basal transcription factor TFIIH to the acidic activation domains of VP16 and p53. Mol Cell Biol 14: 7013-7024.
  • Xu D, Wang Q, Gruber A, Bjorkholm M, Chen Z, Zaid A, Selivanova G, Peterson C, Wiman KG, Pisa P (2000) Downregulation of telomerase reverse transcriptase mRNA expression by wild type p53 in human tumor cells. Oncogene 19: 5123-5133.
  • Zhang L, Yu D, Hu M, Xiong S, Lang A, Ellis LM, Pollock RE (2000) Wild-type p53 suppresses angiogenesis in human leiomyosarcoma and synovial sarcoma by transcriptional suppression of vascular endothelial growth factor expression. Cancer Res 60: 3655-3661.
Document Type
Publication order reference
YADDA identifier
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.